

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50294/016001
	Serial No.	10/521,109
	Applicant	Tedesco et al.
	Filing Date	January 11, 2005
	Group	2165 1644
	IDS Filed	December 19, 2005

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
/PV/	WO 02/30985	4/18/02	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
/PV/	Evans et al., "In Vitro and In Vivo Inhibition of Complement Activity by a Single-Chain Fv Fragment Recognizing Human C5," Mol. Immunol. 32:1183-1195, 1995.					
/PV/	Fitch et al., "Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass," Circulation 100:2499-2506, 1999.					
/PV/	Thomas et al., "Inhibition of Complement Activity by Humanized Anti-C5 Antibody and Single-Chain Fv," Mol. Immunol. 33:1389-1401, 1996.					
/PV/	Wang et al., "Amelioration of Lupus-like Autoimmune Disease in NZBW F1 Mice After Treatment with a Blocking Monoclonal Antibody Specific for Complement Component C5," Proc. Natl. Acad. Sci. U.S.A. 93:8563-8568, 1996.					

EXAMINER /F Pierre Vandervegt/	DATE CONSIDERED 11/13/2007
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	